A61K 40/4221
Cd20
Official title: {cd20}
A61K40/4221 (Cd20) appears on 157 US grants and 400 published applications in this corpus.
Search patents in A61K- Granted patents
- 157
- Published applications
- 400
- Assignees
- 150
- Inventors
- 696
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 1 | 0 |
| 2011 | 2 | 5 |
| 2012 | 0 | 1 |
| 2013 | 1 | 0 |
| 2014 | 0 | 3 |
| 2015 | 0 | 3 |
| 2016 | 2 | 7 |
| 2017 | 2 | 11 |
| 2018 | 2 | 14 |
| 2019 | 15 | 22 |
| 2020 | 8 | 28 |
| 2021 | 17 | 46 |
| 2022 | 12 | 54 |
| 2023 | 22 | 60 |
| 2024 | 13 | 71 |
| 2025 | 31 | 44 |
| 2026 | 28 | 27 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof6 Oct 2026US 12,753,221 B2Abelzeta Inc.
- Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof29 Sep 2026US 12,747,279 B2Abelzeta Inc.
- Chimeric antigen receptors with CD20 safety switch22 Sep 2026US 12,742,001 B2St. Jude Children?S Research Hospital
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Methods and materials for treating cancer24 Sep 2026US 2026/0284192 A1Mayo Foundation for Medical Education and Research
- Gene editing combinations for allogeneic car-t cells with enhanced immune evasion17 Sep 2026US 2026/0275284 A1Kite Pharma, Inc.
- Multi-receptor natural killer cells17 Sep 2026US 2026/0275288 A1Board of Regents, The University of Texas System
- Inhibitory chimeric receptor architectures10 Sep 2026US 2026/0265375 A1Senti Biosciences, Inc.
- Circular rna compositions and methods of use thereof for targeted delivery27 Aug 2026US 2026/0250349 A1
Most cited
By later US patents
- CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies343US 6,410,319 B1City of Hope · 2002
- Bispecific chimeric antigen receptors and encoding polynucleotides thereof92US 9,447,194 B2Seattle Children's Hospital · 2016
- CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell27US 10,253,086 B2Novartis AG · 2019
- Bispecific chimeric antigen receptors and methods of use thereof to treat cancer26US 10,189,903 B2Seattle Children's Hospital · 2019
- Multipartite signaling proteins and uses thereof21US 10,196,444 B2bluebird bio, Inc. · 2019